Target of replication: *A priori* experimental protocols, materials, and confirmatory analysis plans were peer reviewed, [pre-registered][1], and published by [*eLife*][2]. This component includes all data, analysis scripts, and methods for the replication of the experiment reported in Figures 6A-C and Supplemental Table S4 of [Willingham et al. 2012][3]. This experiment assesses the efficacy and safety of anti-CD47 antibody treatment in immune competent mice using a syngeneic model of mammory cancer. <br> ### Contents [Figures component][4] contains a visualization of replication results. These figures are the same as can be found in the Replication Study and include Figure 1 displaying blood toxicity analysis and Figure 2 displaying tumor weights. [Statistical Analyses component][5] contains R scripts that were used for the analysis. [Data component][6] contains data generated from the experimental work and files used in the analysis and generation of figures, which are in .csv format. [Methods component][7] contains methodology details for this replication attempt which were described in the [Registered Report][8]. [Cell line quality control data][9] includes results confirming the cell lines were free of mycoplasma contamination and common mouse pathogens as well as STR DNA profiling of the cell line used. [ELISA component][10] includes the protocol details and data shared by the Weissman lab, Stanford University, for the anti-CD47 antibody, clone MIAP410, used in this replication. [1]: https://osf.io/9gykv/ [2]: http://elifesciences.org/content/4/e04586v1 [3]: http://www.pnas.org/content/109/17/6662 [4]: https://osf.io/84efg/wiki/home/ [5]: https://osf.io/ju36c/wiki/home/ [6]: https://osf.io/43jau/wiki/home/ [7]: https://osf.io/zch4n/wiki/home/ [8]: http://elifesciences.org/content/4/e04586v1 [9]: https://osf.io/9r5hy/wiki/home/ [10]: https://osf.io/werk5/